MDxHealth SA (NASDAQ:MDXH) Short Interest Up 22.2% in June

MDxHealth SA (NASDAQ:MDXH) was the recipient of a large growth in short interest in June. As of June 30th, there was short interest totalling 23,700 shares, a growth of 22.2% from the June 15th total of 19,400 shares. Approximately 0.1% of the shares of the stock are short sold. Based on an average daily volume of 37,800 shares, the short-interest ratio is currently 0.6 days.

MDxHealth Stock Performance

MDXH stock traded up $0.14 during midday trading on Tuesday, reaching $2.90. 23,756 shares of the company’s stock traded hands, compared to its average volume of 60,176. The company has a 50-day simple moving average of $2.72 and a two-hundred day simple moving average of $3.06. MDxHealth has a 1-year low of $2.15 and a 1-year high of $4.64. The company has a current ratio of 1.69, a quick ratio of 1.53 and a debt-to-equity ratio of 5.43.

MDxHealth (NASDAQ:MDXH) last announced its quarterly earnings data on Wednesday, May 1st. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.01). The company had revenue of $19.83 million during the quarter, compared to analyst estimates of $18.32 million. As a group, research analysts predict that MDxHealth will post -1 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MDXH. Perkins Capital Management Inc. lifted its holdings in shares of MDxHealth by 2.7% in the fourth quarter. Perkins Capital Management Inc. now owns 415,225 shares of the company’s stock valued at $1,636,000 after purchasing an additional 11,000 shares in the last quarter. MVM Partners LLC acquired a new position in MDxHealth during the fourth quarter worth approximately $17,906,000. Finally, FAS Wealth Partners Inc. acquired a new position in MDxHealth during the first quarter worth approximately $42,000.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.